Inflammatory bowel disease

PFAS ‘forever chemicals’: Why EPA set federal drinking water limits for these health-harming contaminants

Retrieved on: 
Wednesday, April 10, 2024

The U.S. Environmental Protection Agency now believes there is no safe level for two common PFAS – PFOA and PFOS – in drinking water, and it acknowledges that very low concentrations of other PFAS present human health risks.

Key Points: 
  • The U.S. Environmental Protection Agency now believes there is no safe level for two common PFAS – PFOA and PFOS – in drinking water, and it acknowledges that very low concentrations of other PFAS present human health risks.
  • The agency issued the first legally enforceable national drinking water standards for five common types of PFAS chemicals, as well as PFAS mixtures, on April 10, 2024.

What exactly are PFAS?

  • This is a large group of human-made chemicals – currently estimated to be nearly 15,000 individual chemical compounds – that are used widely in consumer products and industry.
  • They can make products resistant to water, grease and stains and protect against fire.
  • The short answer is that PFAS are harmful to human health and the environment.
  • Some of the very same chemical properties that make PFAS attractive in products also mean these chemicals will persist in the environment for generations.
  • The U.S. Geological Survey estimates common types of PFAS are now in at least 45% of the country’s tap water.

What are the health risks from PFAS exposure?

  • Research consistently demonstrates that PFAS are associated with a variety of adverse health effects.
  • A review by a panel of experts looking at research on PFAS toxicity concluded with a high degree of certainty that PFAS contribute to thyroid disease, elevated cholesterol, liver damage, and kidney and testicular cancer.
  • Additionally, current research suggests that babies exposed prenatally are at higher risk of experiencing obesity, early-onset puberty and reduced fertility later in life.
  • Collectively, this is a formidable list of diseases and disorders.

Who’s regulating PFAS?

  • DuPont called it Teflon, which eventually became a household name for its use on nonstick pans.
  • Decades later, in 1998, Scotchgard maker 3M notified the Environmental Protection Agency that a PFAS chemical was showing up in human blood samples.
  • At the time, 3M said low levels of the manufactured chemical had been detected in people’s blood as early as the 1970s.
  • The Agency for Toxic Substances and Disease Registry has a toxicological profile for PFAS.

How can you reduce your PFAS exposure?

  • The best ways to protect yourself and your family from risks associated with PFAS are to educate yourself about potential sources of exposure.
  • Products labeled as water- or stain-resistant have a good chance of containing PFAS.
  • Strategies for monitoring and reporting PFAS contamination vary by location and PFAS source, so the absence of readily available information does not necessarily mean the region is free of PFAS problems.


Kathryn Crawford receives funding from National Institutes of Health and US Geological Survey.

Emerging Markets Report: Follow the Leader

Retrieved on: 
Tuesday, April 9, 2024

ORLANDO, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- For some time now the market has been in love with Nvidia (NVDA), the behemoth stock which has been to say the least, a bell cow for the market. And while we don’t discuss actual share prices in our pages, preferring to focus instead on the items that historically drive favorable valuations, Nvidia’s price appreciation has been remarkable and is, powered by their revenue growth and the public’s attraction to Artificial Intelligence technology.

Key Points: 
  • And we believe that the intersection of Health Care and Artificial Intelligence is the first half of that formula.
  • With NVIDIA, healthcare institutions can harness the power of AI and high-performance computing (HPC) to define the future of medicine.
  • If the revenue trend continues, analysts, partners, and market interests may follow.
  • And HEALWELL is certainly following the leader, acquiring and developing potentially lucrative Healthcare A.I.

Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 27, 2024

Carlsbad, CA, March 27, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a pre-clinical biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today reported its financial results for the full year 2023 and provided a corporate update.

Key Points: 
  • “2023 was a transformative year for Palisade Bio as we strategically shifted into the autoimmune, inflammatory, and fibrotic disease space, with the focus on our precision medicine approach in inflammatory bowel disease,” commented J.D.
  • “As a result of the progress made by our development team, we are on track to launch the Phase 1 study of PALI-2108 by the end of 2024.
  • Summary of Financial Results for the Year Ended December 31, 2023
    As of December 31, 2023, the Company had cash, cash equivalents and restricted cash of $12.5 million.
  • Net operating loss was $13.1 million for the year ended December 31, 2023 compared to $15.7 million for the year ended December 31, 2022.

Nucleai and GoPath Diagnostics Announce Strategic Collaboration to Provide Integrated AI-powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications

Retrieved on: 
Monday, April 8, 2024

Nucleai , a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration with GoPath Diagnostics , a leading full-service digital pathology and molecular diagnostics laboratory.

Key Points: 
  • Nucleai , a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration with GoPath Diagnostics , a leading full-service digital pathology and molecular diagnostics laboratory.
  • This partnership unites Nucleai and GoPath's complementary skills to expedite the development of new AI-powered clinical research and diagnostics.
  • The integrated solutions will be deployed within a centralized environment that meets the standards of the College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA), Clinical Laboratory Evaluation Program (CLEP), Good Clinical Practice (GCP), and Good Clinical Laboratory Practice (GCLP).
  • Jim Lu, M.D., CEO and Medical Director for GoPath Diagnostics, said: “Our collaboration with Nucleai transforms our capabilities, enabling GoPath to deliver a seamlessly integrated lab workflow.

Clinical Data Supports Novel Continuous Calprotectin Monitoring Wearable for IBD Management by EnLiSense

Retrieved on: 
Monday, April 8, 2024

The study showcases the IBD Aware device's ability to non-invasively monitor calprotectin levels in both active and remission phases of IBD.

Key Points: 
  • The study showcases the IBD Aware device's ability to non-invasively monitor calprotectin levels in both active and remission phases of IBD.
  • These results not only affirm the accuracy of the IBD Aware device, but demonstrate its utility in the shifting paradigm of proactive IBD management that emphasizes continuous, data-driven decision-making.
  • “The IBD Aware device exemplifies our dedication to empowering healthcare professionals and enhancing patient outcomes through remote and continuous monitoring."
  • EnLiSense is pioneering work to build a future where proactive, personalized, and precision remote patient monitoring becomes the standard in chronic disease management.

Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics

Retrieved on: 
Tuesday, April 9, 2024

NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul"). Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics. Cannasoul is founded by the Technion Research & Development Foundation, the commercialization arm of The Technion—Israel Institute of Technology ("the Technion").

Key Points: 
  • NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul").
  • Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics.
  • Cannasoul is founded by the Technion Research & Development Foundation, the commercialization arm of The Technion—Israel Institute of Technology ("the Technion").
  • Synaptogenix, through its partnership with Cannasoul, expanded its stake in PsygaBio, enabling Synaptogenix Chairman Josh Silverman and Director Bruce Bernstein to join PsygaBio's board of directors.

Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market

Retrieved on: 
Friday, March 22, 2024

The latest results reveal gastroenterologists (n=73) have been slow to incorporate the newest entrants into their already bustling armamentarium, though project rapid adoption over the course of 2024.

Key Points: 
  • The latest results reveal gastroenterologists (n=73) have been slow to incorporate the newest entrants into their already bustling armamentarium, though project rapid adoption over the course of 2024.
  • In terms of unaided awareness of the newly approved medications, Omvoh had the highest recall rates, followed closely by Velsipity and more distantly by Entyvio SC.
  • Conversely, but as expected, Entyvio SC is the most familiar among the three, followed by Velsipity and then Omvoh.
  • The adoption trends regarding gastroenterologist trial rates, overall market share, and average patient initiations exhibit a consistent pattern.

Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease

Retrieved on: 
Thursday, March 21, 2024

This approach is widely recognized to promote deeper remission and offer better long-term clinical outcomes1,2.

Key Points: 
  • This approach is widely recognized to promote deeper remission and offer better long-term clinical outcomes1,2.
  • HTL’744 aims to address the significant unmet need of people with IBD that do not achieve satisfactory disease control.
  • The trial will be conducted in the UK and initial data read-outs are anticipated from 2025.
  • EP4 agonists are a recognized and exciting class of drugs with a dual mechanism of action that can resolve inflammation and promote mucosal healing.

Morphic Appoints Dr. Simon Cooper as Chief Medical Officer

Retrieved on: 
Tuesday, March 19, 2024

WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer.

Key Points: 
  • WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer.
  • Dr. Cooper most recently served as Chief Medical Officer of Keros Therapeutics.
  • Of particular relevance to Morphic as we advance MORF-057, is Simon’s experience in the development and approvals for therapeutically effective and commercially successful autoimmune and inflammatory agents in the GI space,” commented Praveen Tipirneni, Chief Executive Officer of Morphic.
  • I am also excited about the prospects for Morphic research programs for small molecules against non-integrin immunology targets and am looking forward to working with the Morphic Team,” commented Dr. Cooper.

HEALWELL AI Announces New Commercial Agreements with WELL HEALTH USA and Circle Medical, Bringing AI-Based Preventative Care Solutions to U.S. Market

Retrieved on: 
Thursday, March 14, 2024

HEALWELL AI has signed services agreements with both WELL Health USA and U.S. based Circle Medical Technologies Inc., which expands its footprint in the U.S. and will enable U.S. healthcare providers with a suite of artificial intelligence (AI) powered preventative care solutions.

Key Points: 
  • HEALWELL AI has signed services agreements with both WELL Health USA and U.S. based Circle Medical Technologies Inc., which expands its footprint in the U.S. and will enable U.S. healthcare providers with a suite of artificial intelligence (AI) powered preventative care solutions.
  • HEALWELL’s Khure Health will integrate its proprietary AI platform with Circle Medical’s electronic medical record system, expanding its footprint to over 30 US states.
  • Enabling WELL USA and Circle Medical providers is a demonstration of this commitment and a major step forward for HEAWELL into the US market.
  • George Favvas, CEO of Circle Medical commented, “We are excited to partner with Khure and bring their AI solutions to the healthcare practitioners we support.